News & Updates
Filter by Specialty:
Pharmacist-led smoking cessation program prompts quit attempts, IBD medication use
A smoking cessation program led by a pharmacist in a specialty medical home is feasible and may even lead to successful quit attempts and improved use of inflammatory bowel disease (IBD) medications, suggest the results of a study.
Pharmacist-led smoking cessation program prompts quit attempts, IBD medication use
04 Dec 2022
Post-PCI bivalirudin infusion reduces death, bleeding vs heparin
Patients with ST-elevation myocardial infarction (STEMI) who undergo primary percutaneous coronary intervention (PCI) have a reduced risk of all-cause death or BARC* type 3–5 bleeding when they receive a bolus plus post-PCI high-dose infusion of bivalirudin compared with heparin monotherapy, results of the BRIGHT**-4 trial showed.
Post-PCI bivalirudin infusion reduces death, bleeding vs heparin
04 Dec 2022
First-line serplulimab + chemo ups survival in extensive-stage SCLC
The addition of serplulimab to chemotherapy in the first-line setting improved overall survival (OS) in patients with extensive-stage small cell lung cancer (SCLC), according to results of the ASTRUM-005 trial.
First-line serplulimab + chemo ups survival in extensive-stage SCLC
02 Dec 2022
ADHD medication use carries no excess risk of cardiovascular diseases
Users of attention-deficit/hyperactivity disorder (ADHD) medications across age groups do not appear to be at increased risk of cardiovascular diseases (CVDs), although a modest risk increase of cardiac arrest or tachyarrhythmias could not be ruled out, according to the results of a meta-analysis.
ADHD medication use carries no excess risk of cardiovascular diseases
02 Dec 2022
SG, HK docs delay prescribing clozapine for treatment-resistant schizophrenia
Clinicians in Singapore and Hong Kong appear to delay the initiation of clozapine for treatment-resistant schizophrenia (TRS) despite familiarity with treatment guidelines, as reported in a study.
SG, HK docs delay prescribing clozapine for treatment-resistant schizophrenia
02 Dec 2022
IV iron cuts risk of HF rehospitalization, CV death in ambulatory HFrEF patients
In a broad range of patients with HFrEF* and iron deficiency, the administration of IV ferric derisomaltose (FDI) was associated with a lower risk of recurrent hospitalization for heart failure (HHF) and cardiovascular (CV) death compared with standard of care (SoC), findings from the IRONMAN** trial have shown.